NCT06886620View on ClinicalTrials.gov

Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

PHASE3TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

February 8, 2017

Study Completion Date

February 8, 2017

Conditions
Intermittent Claudication
Interventions
DRUG

Cilostazol 200 mg

Provided as 1# placebo tablet in the morning and 1# PMR 200 mg/tablet in the evening, orally, for 24 weeks.

DRUG

Cilostazol 100 mg

Provided as 1# Pletaal® 100 mg/tablet, orally twice a day, for 24 weeks.

Trial Locations (5)

112

Cheng Hsin General Hospital, Taipei

333

Chang Gung Memorial Hospital Linkou, Taoyuan District

10016

National Taiwan University Hospital, Taipei

10449

Mackay Memorial Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Genovate Biotechnology Co., Ltd.,

INDUSTRY

NCT06886620 - Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication | Biotech Hunter | Biotech Hunter